Table 3.

LASSO regression multivariate analysis of nSUV metrics and ≥esophagitis grade 2 (N=79), and the symptom progression prediction model construction from grade 0 esophagitis patients at time of the PET study (N=43) Using 3-fold cross-validation repeated for 100 iterations. The median model order, mean AUC value with standard deviation, and the most prevelant recurring model features in the cross-validation process are listed.

Feature Class	Endpoint	Model Order	AUCmean* (S.D.)	Top Recurring Occurrence†
nSUV**	Mid-treatment ≥Grade 2	5	0.83 (±0.07)	nSUVMean, nSUVLen30, nSUVAxMax3, nSUVLen20, nSUVAxMax1
	Treatment Max ≥Grade 2	4	0.88 (±0.05)	nSUVLen40, nSUVMean, nSUVLen30, nSUVAxMax1
DVH††	Mid-treatment ≥Grade 2	3	0.52 (±0.07)	LE10100%, LE50100%, MED
	Treatment Max ≥Grade 2	3	0.76 (±0.12)	Dmax, LE40100%, V50
nSUV** & DVH††	Mid-treatment ≥Grade 2	6	0.81 (±0.07)	nSUVMean, nSUVAxMax5, nSUVLen40, LE50100%, nSUVAxMax1
	Treatment Max ≥Grade 2	5	0.91 (±0.06)	nSUVMean, LE50100%, nSUVLen40, LE30100%, nSUVLen30
DVH††	Symptom Progression ≥Grade 2	3	0.67 (±0.13)	Dmax, V30, LE30100%
nSUV**		3	0.75 (±0.10)	nSUVLen30, nSUVLen40, nSUVAxMax1
nSUV** & DVH††		4	0.72 (±0.12)	nSUVLen30, nSUVLen40, nSUVAxMax1, LE40100%

^*Mean area under the curve from repeated cross-validation.

^†Dose and normalized uptake abbreviations defined in the methods section.

^**Normalized FDG uptake

^††Dose-volume histogram